Who should receive an implantable cardioverter-defibrillator after myocardial infarction?

Area of Science:

• Cardiology
• Electrophysiology
• Preventive Medicine

Background:

• Cardiovascular mortality is declining, yet sudden cardiac death (SCD) incidence is increasing.
• Patients surviving myocardial infarction (MI) with reduced ejection fraction face a particularly high risk of SCD.
• Implantable cardioverter-defibrillators (ICDs) have significantly advanced SCD prevention, but optimal risk stratification in post-MI patients remains an area of active research.

Purpose of the Study:

• To review current indications and optimal timing for ICD implantation for primary and secondary SCD prevention post-MI.
• To discuss conventional and investigational risk stratification methods in post-MI patients.
• To examine ongoing controversies regarding ICD implantation in specific patient subgroups.

Main Methods:

• Literature review of current guidelines and clinical studies.
• Analysis of risk stratification techniques for sudden cardiac death.
• Discussion of evidence supporting ICD use in post-myocardial infarction populations.

Main Results:

• Current guidelines recommend ICDs for specific post-MI patients based on ejection fraction and time since infarction.
• Risk stratification involves various clinical, imaging, and electrophysiological parameters.
• Controversies persist regarding ICD implantation in select populations, such as those with early post-MI or specific comorbidities.

Conclusions:

• ICD implantation is crucial for preventing SCD in high-risk post-MI patients.
• Accurate risk stratification is essential for appropriate patient selection and optimizing ICD therapy.
• Further research is needed to refine indications and address controversies in ICD use for SCD prevention.